New drug aims to tame rare blood disorder flares

NCT ID NCT05334368

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests a drug called depemokimab in adults with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause organ damage. The trial includes 123 people whose HES is not well controlled despite standard therapy. Participants receive either depemokimab or a placebo for 52 weeks, and researchers track how many disease flares occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: depemokimab
What this could lead to: If successful, depemokimab could offer a new option to help control HES and reduce the number of disease flares.
What could go wrong: This is a Phase 3 trial, but results are not yet known. The drug may not reduce flares more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypereosinophilic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPEREOSINOPHILIC SYNDROME

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

San Diego, California, 920237, United States
GSK Investigational Site
COMPLETED

Atlanta, Georgia, 30322, United States
GSK Investigational Site
RECRUITING

Boston, Massachusetts, 02111, United States
GSK Investigational Site
WITHDRAWN

Southfield, Michigan, 48075, United States
GSK Investigational Site
WITHDRAWN

Rochester, Minnesota, 55905, United States
GSK Investigational Site
COMPLETED

Manhasset, New York, 11030, United States
GSK Investigational Site
RECRUITING

Cincinnati, Ohio, 45229, United States
GSK Investigational Site
RECRUITING

Columbus, Ohio, 43212, United States
GSK Investigational Site
RECRUITING

Charleston, South Carolina, 29425, United States
GSK Investigational Site
COMPLETED

Nashville, Tennessee, 37208, United States
GSK Investigational Site
RECRUITING

Salt Lake City, Utah, 84132, United States
GSK Investigational Site
RECRUITING

Buenos Aires, C1425BEN, Argentina
GSK Investigational Site
RECRUITING

Florida, 1602, Argentina
GSK Investigational Site
RECRUITING

La Plata, B1900, Argentina
GSK Investigational Site
RECRUITING

Mar del Plata, 7600, Argentina
GSK Investigational Site
RECRUITING

Quilmes, 1878, Argentina
GSK Investigational Site
COMPLETED

Garran, Australian Capital Territory, 2606, Australia
GSK Investigational Site
RECRUITING

Brussels, 1070, Belgium
GSK Investigational Site
RECRUITING

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
GSK Investigational Site
RECRUITING

Blumenau, 89030-101, Brazil
GSK Investigational Site
RECRUITING

Rio de Janeiro, 21.941-913, Brazil
GSK Investigational Site
RECRUITING

Sorocaba, 18040-425, Brazil
GSK Investigational Site
RECRUITING

Ottawa, Ontario, K1H 1E4, Canada
GSK Investigational Site
RECRUITING

Toronto, Ontario, M5G 1X5, Canada
GSK Investigational Site
RECRUITING

Beijing, 100730, China
GSK Investigational Site
RECRUITING

Changsha, 410008, China
GSK Investigational Site
RECRUITING

Guangzhou, 510080, China
GSK Investigational Site
RECRUITING

Guangzhou, 510515, China
GSK Investigational Site
RECRUITING

Harbin, 150010, China
GSK Investigational Site
RECRUITING

Nanchang, 330006, China
GSK Investigational Site
RECRUITING

Shanghai, 200025, China
GSK Investigational Site
RECRUITING

Suzhou, 215006, China
GSK Investigational Site
RECRUITING

Wuhan, 430022, China
GSK Investigational Site
RECRUITING

Brno-Bohunice, 625 00, Czechia
GSK Investigational Site
RECRUITING

Hradec Králové, 500 05, Czechia
GSK Investigational Site
RECRUITING

Prague, 14059, Czechia
GSK Investigational Site
RECRUITING

Ústí nad Labem, 40113, Czechia
GSK Investigational Site
RECRUITING

Odense C, 5000, Denmark
GSK Investigational Site
RECRUITING

Bad Bramstedt, 24576, Germany
GSK Investigational Site
RECRUITING

Mannheim, 68167, Germany
GSK Investigational Site
RECRUITING

Athens, 10676, Greece
GSK Investigational Site
WITHDRAWN

Rio Patras, 26054, Greece
GSK Investigational Site
RECRUITING

Pokfulam, Hong Kong
GSK Investigational Site
RECRUITING

Ramat Gan, 52621, Israel
GSK Investigational Site
WITHDRAWN

Tel Aviv, 64239, Israel
GSK Investigational Site
RECRUITING

Bologna, 40138, Italy
GSK Investigational Site
RECRUITING

Catania, 95123, Italy
GSK Investigational Site
RECRUITING

Milan, 20132, Italy
GSK Investigational Site
RECRUITING

Naples, 80131, Italy
GSK Investigational Site
RECRUITING

Novara, 28100, Italy
GSK Investigational Site
RECRUITING

Pavia, 27100, Italy
GSK Investigational Site
RECRUITING

Roma, 00168, Italy
GSK Investigational Site
RECRUITING

Treviso, 31100, Italy
GSK Investigational Site
RECRUITING

Verona, 37134, Italy
GSK Investigational Site
RECRUITING

Aomori, 030-8553, Japan
GSK Investigational Site
RECRUITING

Aomori, 036-8563, Japan
GSK Investigational Site
RECRUITING

Chiba, 272-8516, Japan
GSK Investigational Site
RECRUITING

Gifu, 509-6134, Japan
GSK Investigational Site
RECRUITING

Hyōgo, 670-8540, Japan
GSK Investigational Site
RECRUITING

Kanagawa, 259-1143, Japan
GSK Investigational Site
RECRUITING

Miyagi, 980-8574, Japan
GSK Investigational Site
RECRUITING

Tokyo, 105-8471, Japan
GSK Investigational Site
RECRUITING

Tokyo, 142-8666, Japan
GSK Investigational Site
RECRUITING

Wakayama, 641-8509, Japan
GSK Investigational Site
RECRUITING

Yamanashi, 409-3898, Japan
GSK Investigational Site
RECRUITING

Guadalajara, 44130, Mexico
GSK Investigational Site
RECRUITING

Monterrey, 64060, Mexico
GSK Investigational Site
RECRUITING

Veracruz, 94534, Mexico
GSK Investigational Site
RECRUITING

Chęciny, 26-060, Poland
GSK Investigational Site
RECRUITING

Lodz, 90-153, Poland
GSK Investigational Site
RECRUITING

Bucharest, 020125, Romania
GSK Investigational Site
RECRUITING

Bucharest, 31281, Romania
GSK Investigational Site
RECRUITING

Cluj-Napoca, 400124, Romania
GSK Investigational Site
RECRUITING

Gwangju, 61469, South Korea
GSK Investigational Site
RECRUITING

Jeonju, 561-712, South Korea
GSK Investigational Site
RECRUITING

Kangwondo, 26426, South Korea
GSK Investigational Site
RECRUITING

Seoul, 03722, South Korea
GSK Investigational Site
RECRUITING

Seoul, 06351, South Korea
GSK Investigational Site
RECRUITING

Seoul, 06591, South Korea
GSK Investigational Site
RECRUITING

Seoul, 110-744, South Korea
GSK Investigational Site
RECRUITING

Seoul, 136-705, South Korea
GSK Investigational Site
RECRUITING

Seoul, 138-736, South Korea
GSK Investigational Site
RECRUITING

Suwon Kyunggi-do, 16499, South Korea
GSK Investigational Site
RECRUITING

Barcelona, 08036, Spain
GSK Investigational Site
RECRUITING

Granada, 18014, Spain
GSK Investigational Site
RECRUITING

Madrid, 28008, Spain
GSK Investigational Site
RECRUITING

Madrid, 28031, Spain
GSK Investigational Site
RECRUITING

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site
RECRUITING

Salamanca, 37007, Spain
GSK Investigational Site
RECRUITING

Valencia, 46026, Spain
GSK Investigational Site
RECRUITING

Zaragoza, 50009, Spain
GSK Investigational Site
RECRUITING

Leicester, LE3 9QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.